Research map: Emerging Strategies Targeting the PI3K/AKT/mTOR Pathway in HR+/HER2– Advanced Breast Cancer

Back to the article

Papers in this map

  1. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation · Mark E. Robson · 2017 · 3330 citations · Cited by this paper
  2. Sibeprenlimab: First Approval · 2026 · Related
  3. Cancer statistics, 2025 · Rebecca L. Siegel · 2025 · 2992 citations · Cited by this paper
  4. The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir · 2026 · Related
  5. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer · José Baselga · 2011 · 2874 citations · Cited by this paper
  6. Ecnoglutide: First Approvals · 2026 · Related
  7. Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer · Fabrice André · 2019 · 2663 citations · Cited by this paper
  8. Recaticimab: The First Fc-Engineered PCSK9 Monoclonal Antibody for More Long-Lasting Effect in Lipid Lowering · 2026 · Related
  9. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer · Antonino Glaviano · 2023 · 2116 citations · Cited by this paper
  10. Etripamil: First Approval · 2026 · Related
  11. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy · George W. Sledge · 2017 · 1707 citations · Cited by this paper
  12. Long-Acting Lipoglycopeptide Treatment of Invasive Gram-Positive Infections · 2026 · Related
  13. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer · Seock‐Ah Im · 2019 · 1043 citations · Cited by this paper
  14. Emerging Cardiorenal Protective Therapies in Lupus Nephritis · 2026 · Related
  15. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer · Dennis J. Slamon · 2019 · 874 citations · Cited by this paper
  16. Reframing the High-density Lipoprotein (HDL) Hypothesis in Light of Clinical Trials of Cholesterol Ester Transfer Protein (CETP) Inhibitors · 2026 · Related
  17. Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer · María Teresa Herrera-Abreu · 2016 · 804 citations · Cited by this paper
  18. Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here · 2026 · Related
  19. Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer · Nicholas C. Turner · 2023 · 783 citations · Cited by this paper
  20. The Role of β-Blockers in the Evolving Treatment Landscape of Resistant Hypertension · 2026 · Related
  21. Breast cancer statistics 2024 · Angela N. Giaquinto · 2024 · 767 citations · Cited by this paper
  22. Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis · Shidong Jia · 2008 · 692 citations · Cited by this paper
  23. The PIK3CA gene is mutated with high frequency in human breast cancers · Kurtis E. Bachman · 2004 · 668 citations · Cited by this paper
  24. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1 · Fabrice André · 2020 · 621 citations · Cited by this paper
  25. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor · Dejan Juric · 2014 · 596 citations · Cited by this paper
  26. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2 · Martine J Piccart · 2014 · 579 citations · Cited by this paper
  27. The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations · Chuan‐Hsiang Huang · 2007 · 569 citations · Cited by this paper
  28. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial · José Baselga · 2017 · 548 citations · Cited by this paper
  29. Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis · Denise Aysel Yardley · 2013 · 527 citations · Cited by this paper
  30. Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials · Christine M. Fritsch · 2014 · 510 citations · Cited by this paper
  31. Mutation of the PIK3CA oncogene in human cancers · Bedri Karakas · 2006 · 505 citations · Cited by this paper
  32. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation · Pascal Furet · 2013 · 489 citations · Cited by this paper
  33. Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background · Barry R. Davies · 2012 · 473 citations · Cited by this paper
  34. Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline · Catherine H. Van Poznak · 2015 · 405 citations · Cited by this paper
  35. Frequency and spectrum of PIK3CA somatic mutations in breast cancer · Olga Martínez‐Sáez · 2020 · 394 citations · Cited by this paper
  36. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial · Angelo Di Leo · 2017 · 389 citations · Cited by this paper
  37. ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer · Todd W. Miller · 2011 · 344 citations · Cited by this paper
  38. Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors · Sherri Z. Millis · 2016 · 317 citations · Cited by this paper
  39. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial · Ian E. Krop · 2016 · 300 citations · Cited by this paper

Source: OpenAlex (CC0)